耐火性慢性咳中的P2X3受体抗剂 (AF-219):一个随机,双盲,安慰剂控制的第二阶段研究
Rayid Abdulqawi1, Rachel Dockry1, Kimberley Holt1
1Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; University Hospital of South Manchester, Education and Research Centre, University Hospital of South Manchester, Manchester, UK.
口服P2X3抗剂AF-219显著降低了耐火性慢性咳患者的咳频率. 这项研究强调P2X3受体对抗剂是慢性咳的有希望的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 气道虚 afferent神经上的P2X3受体与感官神经元过敏有关.
- 这些受体可能会调解咳反射敏感化,导致慢性咳.
- 耐火性慢性咳是一个重要的未满足的医疗需求.
研究的目的:
- 为了评估AF-219的疗效,一种新的口服P2X3抗剂,在减少咳频率.
- 研究P2X3受体在耐火性慢性咳病理生理学中的作用.
主要方法:
- 进行了一项双盲,安慰剂控制,两期的交叉研究.
- 耐药性慢性咳患者接受AF-219 (600毫克每天两次) 或安慰剂2周,随后进行2周的洗,然后接受替代治疗.
- 使用24小时的门诊咳记录来评估白天咳的频率.
主要成果:
- 与安慰剂相比,AF-219治疗导致咳频率减少75% (p=0.0003).
- 平均白天咳频率从每小时37次下降到每小时11次,AF-219.
- 所有接受AF-219治疗的患者报告了味觉障碍,导致六次戒断.
结论:
- P2X3受体对抗作用有效降低了耐火性慢性咳患者的咳频率.
- AF-219显示出作为一种新类抗咳药物的潜力.
- 准P2X3受体为咳过敏提供了一个有希望的治疗策略.
相关概念视频
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Chronic Obstructive Pulmonary Disease II: Emphysema
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...


